^
Association details:
| Biomarker: | NTRK3 fusion |
|---|---|
| Cancer: | Solid Tumor |
| Drug Class: | Trk inhibitor |
| Direction: | Sensitive |
Evidence:
Source:
Title:
100P - Characteristics and outcomes of patients (pts) with NTRK fusion-positive (NTRK+) metastatic / locally advanced (LA) solid tumours receiving non-TRK inhibitor (TRKi) standard of care (SoC), and prognostic value of NTRK fusions in clinical practice
Published date:
09/13/2021
Excerpt:
...small cohort of TRKi-naïve pts, OS was similarly poor in pts with NTRK+ metastatic/LA cancers vs matched NTRK– pts; this contrasts with improved OS in pts with NTRK+ tumours who receive TRKi therapy.
